Latest News

Big multiple sclerosis breakthrough: Phase 1 trial safely resets patients' immune systems and reduces attack on myelin protein

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent. The therapy used billions of patients' own specially processed blood cells to create tolerance to myelin, the insulating layer that forms around nerves. In MS, the immune system attacks myelin. The approach left the normal immune system intact.
View full story

Post your comment.


  • Molecular trigger for cerebral cavernous malformation identified

  • Researchers urge caution in prescribing commonly used drug to treat ADHD

  • Even the elderly can recover from a severe traumatic brain injury

  • Instrument to measure brand embarrassment developed by economists

  • White matter damage caused by 'skunk-like' cannabis, study shows

  • Cognitive behavior therapy can help overcome fear of the dentist

  • How can I tell if they're lying?

  • Amblyopia, not strabismus, identified as key contributor to slow reading in school-age children

  • Visual stress could be a symptom of Chronic Fatigue Syndrome, research suggests

  • Lower availability of omega-3 fatty acids in the body associated with bipolar disorder